Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (233)	11/16/2004 4:09:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Dr. Colin Goddard: There's an outstanding question, that absolutely fascinates me. The presentations where you used to crow about two IND-track projects, the OSI project for asthma and the Solvay project for CHF, are documented here at SI. As SLV320 was advancing at Solvay, why did you suddenly go silent about the adenosine receptor program in general, and re. SLV320 in particular? I'm not implying that there's anything sinister. But it just seems particularly weird. What am I missing? You went silent "pre-angio, pre-IMCL, etc." at a point where the stock needed goosing, so it's not like you'd have forgotten about a chunk of CHF. Thanks, in advance, for any answer. Your 10-K filings have been insufficient. These projects went poof. This persisting policy of silence on this front is sore thumb stuff. You're downright weird here. As of this month, SLV320 is still listed as heading for phase II, Solvay..... solvay.com Richard Harmon